Heidelberg, July 22nd, 2007 - SYGNIS Pharma AG has successfully completed the
clinical phase IIa-study (AXIS) in stroke. AXIS was a multicenter, doubleblind,
placebo-controlled dose escalation study. The comprehensive analysis of the
study data showed that the primary and secondary endpoints have been achieved
and that the use of AX200 in stroke patients can be considered to be safe.
